Dr Reddy's Shares Dip Amid Semaglutide Supply Snag, Brokerages Adjust Targets

Shares of Dr Reddy's Laboratories have experienced a notable decline over the past two trading days, falling approximately 9%, following an announcement regarding delayed commercial supplies of its semaglutide product. The pharmaceutical major cited a quality-related issue with its Active Pharmaceutical Ingredient (API) as the cause for the disruption. This development has prompted several brokerage firms to revise their financial outlooks for Dr Reddy's. While the long-term prospects for the company's semaglutide offering, a GLP-1 receptor agonist targeting diabetes and weight management, are still viewed favorably, analysts have adjusted near-term earnings estimates and target prices downwards. The revisions reflect concerns over execution risks and a potentially slower-than-anticipated product ramp-up. Semaglutide represents a significant growth driver for pharmaceutical companies globally, with a rapidly expanding market. Dr Reddy's entry into this segment was closely watched, and the supply interruption introduces a degree of uncertainty regarding its immediate market penetration and revenue contribution from this key product. The company's ability to swiftly resolve the API quality issue and ensure consistent supply will be critical in mitigating further investor apprehension and maintaining its competitive positioning in this lucrative therapeutic area. The market's reaction underscores the sensitivity of pharmaceutical stock valuations to manufacturing integrity and timely product launches.